Mitochondria-targeting compounds for management of metabolic and hemostatic abnormalities associated with heart dysfunctions in experimental type 2 diabetes Cover

.blurhash-client-img { display: none !important; }

Mitochondria-targeting compounds for management of metabolic and hemostatic abnormalities associated with heart dysfunctions in experimental type 2 diabetes

Endocrine Regulations

Volume 59 (2025): Issue 1 (January 2025)

By: Tamara Kuchmerovska, Lesya Yanitska, Oksana Horkunenko, Tetiana Tykhonenko, Liliya Kalachniuk and Irina Pryvrotska

Open Access

|Dec 2025

Download Article

Download the full article as a PDF file.

DOI: https://doi.org/10.2478/enr-2025-0028 | Journal eISSN: 1336-0329 | Journal ISSN: 1210-0668

Journal RSS Feed

Language: English

Page range: 244 - 254

Published on: Dec 12, 2025

Published by: Slovak Academy of Sciences, Institute of Experimental Endocrinology

In partnership with: Paradigm Publishing Services

Publication frequency: 1 issue per year

Keywords:

type 2 diabetes mellitus,

NAD+/NADH ratio,

mitochondria-targeted compounds

Related subjects:

Molecular biology,

Basic medical science,

Basic medical science, other,

Clinical medicine,

Internal medicine,

Endocrinology, diabetology

© 2025 Tamara Kuchmerovska, Lesya Yanitska, Oksana Horkunenko, Tetiana Tykhonenko, Liliya Kalachniuk, Irina Pryvrotska, published by Slovak Academy of Sciences, Institute of Experimental Endocrinology
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.

Previous article Volume 59 (2025): Issue 1 (January 2025)Next article